Literature DB >> 27263935

Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas.

Jelte Helfferich1, Ronald Nijmeijer2, Oebele F Brouwer3, Maartje Boon3, Annemarie Fock3, Eelco W Hoving4, Lisethe Meijer5, Wilfred F A den Dunnen2, Eveline S J M de Bont6.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder, associated with a variable clinical phenotype including café-au-lait spots, intertriginous freckling, Lisch nodules, neurofibromas, optic pathway gliomas and distinctive bony lesions. NF1 is caused by a mutation in the NF1 gene, which codes for neurofibromin, a large protein involved in the MAPK- and the mTOR-pathway through RAS-RAF signalling. NF1 is a known tumour predisposition syndrome, associated with different tumours of the nervous system including low grade gliomas (LGGs) in the paediatric population. The focus of this review is on grade I pilocytic astrocytomas (PAs), the most commonly observed histologic subtype of low grade gliomas in NF1. Clinically, these PAs have a better prognosis and show different localisation patterns than their sporadic counterparts, which are most commonly associated with a KIAA1549:BRAF fusion. In this review, possible mechanisms of tumourigenesis in LGGs with and without NF1 will be discussed, including the contribution of different signalling pathways and tumour microenvironment. Furthermore we will discuss how increased understanding of tumourigenesis may lead to new potential targets for treatment.
Copyright © 2016 The Author(s). Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  BRAF:KIAA1549 fusion; Low grade glioma; NF1 gene; Neurofibromatosis; Pilocytic astrocytoma

Mesh:

Year:  2016        PMID: 27263935     DOI: 10.1016/j.critrevonc.2016.05.008

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  31 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Partial unilateral lentiginosis with ipsilateral Lisch nodules and pilocytic astrocytoma: Is this a type of segmental neurofibromatosis?

Authors:  Yasemin Erdem; Ilknur Kivanc Altunay; Ezgi Ozkur; Eyup Duzgun
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

Review 3.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 4.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

Authors:  E Alejandro Sweet-Cordero; Jaclyn A Biegel
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

5.  Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.

Authors:  Eva Trevisson; Matteo Cassina; Enrico Opocher; Virginia Vicenzi; Marta Lucchetta; Raffaele Parrozzani; Giacomo Miglionico; Rodica Mardari; Elisabetta Viscardi; Edoardo Midena; Maurizio Clementi
Journal:  J Neurooncol       Date:  2017-06-02       Impact factor: 4.130

Review 6.  Germline genetic landscape of pediatric central nervous system tumors.

Authors:  Ivo S Muskens; Chenan Zhang; Adam J de Smith; Jaclyn A Biegel; Kyle M Walsh; Joseph L Wiemels
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

7.  Optic pathway glioma and endocrine disorders in patients with and without NF1.

Authors:  Merav Gil Margolis; Michal Yackobovitz-Gavan; Helen Toledano; Ariel Tenenbaum; Roni Cohen; Moshe Phillip; Shlomit Shalitin
Journal:  Pediatr Res       Date:  2022-05-10       Impact factor: 3.756

8.  A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.

Authors:  Nicole J Ullrich; Sanjay P Prabhu; Alyssa T Reddy; Michael J Fisher; Roger Packer; Stewart Goldman; Nathan J Robison; David H Gutmann; David H Viskochil; Jeffrey C Allen; Bruce Korf; Alan Cantor; Gary Cutter; Coretta Thomas; John P Perentesis; Tomoyuki Mizuno; Alexander A Vinks; Peter E Manley; Susan N Chi; Mark W Kieran
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

9.  The molecular landscape of glioma in patients with Neurofibromatosis 1.

Authors:  Fulvio D'Angelo; Michele Ceccarelli; Luciano Garofano; Jing Zhang; Véronique Frattini; Francesca P Caruso; Genevieve Lewis; Kristin D Alfaro; Luc Bauchet; Giulia Berzero; David Cachia; Mario Cangiano; Laurent Capelle; John de Groot; Francesco DiMeco; François Ducray; Walid Farah; Gaetano Finocchiaro; Stéphane Goutagny; Carlos Kamiya-Matsuoka; Cinzia Lavarino; Hugues Loiseau; Véronique Lorgis; Carlo E Marras; Ian McCutcheon; Do-Hyun Nam; Susanna Ronchi; Veronica Saletti; Romuald Seizeur; John Slopis; Mariona Suñol; Fanny Vandenbos; Pascale Varlet; Dominique Vidaud; Colin Watts; Viviane Tabar; David E Reuss; Seung-Ki Kim; David Meyronet; Karima Mokhtari; Hector Salvador; Krishna P Bhat; Marica Eoli; Marc Sanson; Anna Lasorella; Antonio Iavarone
Journal:  Nat Med       Date:  2018-12-10       Impact factor: 53.440

10.  Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.

Authors:  Jennifer L Griffith; Stephanie M Morris; Jasia Mahdi; Manu S Goyal; Tamara Hershey; David H Gutmann
Journal:  Neurol Clin Pract       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.